HCV core antigen is a useful predictor during pegylated-interferon/ribavirin therapy in patients with hepatitis C virus genotype 1b

Zhijuan Fan, MSc\textsuperscript{a,b,c}, Junfeng Liu, MSc\textsuperscript{d}, Fengmei Wang, PhD\textsuperscript{b,c,e}, Jingmin Liu, BS\textsuperscript{f}, Xian Ding, BS\textsuperscript{a,b,c}, Shuye Liu, PhD\textsuperscript{a,b,c,*}

Abstract
Enzyme immunoassays for quantifying hepatitis C virus (HCV) core antigen (Ag) have been proposed as an alternative to HCV RNA detection. The present study aimed to investigate the early kinetics of serum HCVcAg and its usefulness in predicting virological responses.

The clinical data of 135 patients with chronic hepatitis C treated with pegylated interferon alpha (PEG-IFN-α) and ribavirin was retrospectively collected. The patients were grouped according to their treatment outcomes as follows: sustained virological response (SVR), nonsustained virological response (N-SVR), and relapse.

Higher HCVcAg and HCV RNA levels were observed in patients in the N-SVR group than in the other groups at baseline. HCVcAg better predicted rapid virological response (RVR) compared with HCV RNA and had a predictive value similar to that of HCV RNA for SVR and early virological response. In the relapse group, HCV RNA decreased to 0 after 48 weeks, whereas HCVcAg was still detectable, indicating that HCVcAg more sensitively predicted relapse in antiviral therapy than HCV RNA.

For patients treated with PEG-IFN-α and ribavirin, HCVcAg may more sensitively predict relapse than HCV RNA.

Abbreviations: ALT = alanine aminotransferase, AST = aspartate aminotransferase, AUROC = area under the univariate receiver operating characteristic, CHC = chronic hepatitis C, EVR = early virological response, HCV = hepatitis C virus, HCVcAg = HCV core antigen, N-SVR = nonsustained virological response, PCR = polymerase chain reaction, PEG-IFN = pegylated interferon, RVR = rapid virological response, SVR = sustained virological response.

Keywords: chronic hepatitis C, hepatitis C virus core antigen, hepatitis C virus RNA, relapse, sustained virological response.

1. Introduction
Chronic hepatitis C virus (HCV) infection results in progressive disease and afflicts more than 185 million people worldwide.\textsuperscript{[1]} Progression of hepatic fibrosis, cirrhosis, or carcinoma is consistently observed in patients with chronic HCV infection.\textsuperscript{[2]}

Treatment and monitoring of HCV infection are a great challenge for many countries, especially in developing countries. In China, HCV genotype 1b accounts for 70% of all cases of HCV infection.\textsuperscript{[3]} Treatment of HCV genotype 1 has evolved from pegylated interferon (PEG-IFN) and ribavirin to direct-acting antiviral agents. In recent years, new treatments for chronic infection with HCV genotype 1b have emerged, such as the combination of simprevir and sofosbuvir\textsuperscript{[4]} and that of ledipasvir and sofosbuvir.\textsuperscript{[5]} Although the treatment response of chronic hepatitis C (CHC) has been improved with combination antiviral drug therapy, about 50% of patients with CHC genotype 1b do not achieve sustained virological response (SVR). In addition, the high cost of treatment and adverse effects often lead to treatment failure.\textsuperscript{[6]} Therefore, a predictive indicator would enable prompt treatment when adverse effects occur.

HCV RNA quantification has been used to assess early virological response (EVR) in the treatment of chronic HCV infection owing to its high sensitivity (detection limit as low as 50 IU/mL), high specificity, and reproducibility. However, the high cost associated with this assay hinders its use in resource-limited settings.\textsuperscript{[7]} In addition, like other molecular assays typically performed in batches, HCV RNA quantification lacks a short turn-around time, delaying clinical decision-making.\textsuperscript{[8]}

The CE-marked HCV core antigen (HCVcAg) quantification assay (ARCHITECT HCV Ag assay; Abbott Diagnostics, Wiesbaden, Germany) is a rapid, affordable, and simplified method.\textsuperscript{[9]} Many studies have found a correlation between the levels of serum HCVcAg and HCV RNA in patients with CHC.\textsuperscript{[10–15]} Recently, serum HCVcAg levels have been reported to predict early SVR in patients with HCV genotype 1b.\textsuperscript{[16,17]} However, it is not clear whether HCVcAg levels can predict SVR and relapse in Chinese patients infected with HCV genotype 1b.
The present study aimed to compare the levels of HCVcAg, HCV RNA, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) between patients with different treatment outcomes: SVR, nonsustained virological response (N-SVR), and relapse (positive after 24 weeks of treatment). In addition, the predictive roles of HCVcAg at different phases of HCV genotype 1b infection treatment were explored.

2. Materials and methods

2.1. Patients

The clinical data of 135 patients (65 men and 70 women) treated with PEG-IFN-α and ribavirin for HCV genotype 1b infection were retrospectively collected. This study was approved by the Tianjin Third Central Hospital Ethics Committee (Approval Number: IRB2014-019-02). Patients with the following conditions were excluded: liver dysfunction, pregnancy, major diseases, amnesia, neutrophil count <1.5 x 10^9/L, white blood cell counts <3 x 10^9/L, and platelet counts <90 x 10^9/L.

2.2. Treatment protocol

Patients were treated with PEG-IFN-α (Peg-Intron; Schering-Plough, Kenilworth, NJ; 180 μg/wk for body weight ≥65 kg and 135 μg/wk for body weight <65 kg) in combination with ribavirin (Rebetol; Schering-Plough; 1000 mg/d for body weight ≥65 kg and 800 mg/d for body weight <65 kg). After the initial 12-week treatment, if the HCV RNA level decreased at least by 2 log10 or the viral load was 5.00 ± 1.19 log10 fM at baseline. Patients were categorized according to treatment outcome: SVR, relapse (positive after 24 weeks of treatment), and N-SVR. The baseline characteristics of these patients are shown in Table 1. Compared with patients in the N-SVR group, patients in the SVR group were older and showed significantly higher levels of HCVcAg and HCV RNA and significantly lower levels of ALT and AST at baseline. Patients in the N-SVR group were significantly older and showed significantly higher levels of HCVcAg and HCV RNA at baseline, in comparison with patients in the relapse group. No significant difference in parameters, except HCVcAg between the SVR and relapse groups, was observed at baseline. The baseline HCVcAg levels were significantly correlated with levels of HCV RNA (r = 0.986, P = 0.001), ALT (r = 0.416, P = 0.001), and AST/ALT (r = 0.201, P = 0.001).

2.3. Virological and serological testing

HCV RNA levels were measured at 0, 4, 12, 24, 36, 48, and 72 weeks of treatment using real-time polymerase chain reaction (PCR) with a lower limit of detection of 43 IU/mL. The parallel normality and homogeneity of variance tests were both examined. Data with non-normal distributions were processed using natural logarithmic transformation before statistical analysis. Comparison between 2 groups was performed using t tests, and comparisons among multiple groups were performed using analysis of variance. HCV RNA loading capacity and quantitative HCVcAg were both converted to log10 values before statistical analysis. Comparisons of categorical data were performed using the χ² test. Pearson method was used to analyze the correlation of continuous variables. P < .05 was considered statistically significant.

3. Results

3.1. Baseline characteristics of patients

A total of 135 patients (age range, 29–70 years; average, 50.3 years) infected with HCV genotype 1b were included. The mean viral load was 6.12 ± 1.20 log10 IU/mL, and the HCV antigen level was 5.00 ± 1.19 log10 fM at baseline. Patients were categorized according to treatment outcome: SVR, relapse (positive after 24 weeks of treatment), and N-SVR. The baseline characteristics of these patients are shown in Table 1. Compared with patients in the SVR group, patients in the N-SVR group were older and showed significantly higher levels of HCVcAg and HCV RNA and significantly lower levels of ALT and AST at baseline. Patients in the N-SVR group were significantly older and showed significantly higher levels of HCVcAg and HCV RNA at baseline, in comparison with patients in the relapse group. No significant difference in parameters, except HCVcAg between the SVR and relapse groups, was observed at baseline. The baseline HCVcAg levels were significantly correlated with levels of HCV RNA (r = 0.986, P = 0.001), ALT (r = 0.416, P = 0.001), and AST/ALT (r = 0.201, P = 0.001).

3.2. Influence of baseline parameters on treatment outcome

Table 1 shows that to determine the factors that correlated with different disease phases in patients with HCV genotype 1b, 7 variables—gender, HCV genotype, age, ALT level, AST level, HCV RNA, and HCVcAg—were analyzed. Regression analysis showed that

| Table 1 | Baseline patient characteristics. |
|---------|----------------------------------|
|         | SVR (n = 90) | Relapse (n = 20) | N-SVR (n = 25) | P |
| Male    | 42           | 11             | 12            | .001 |
| Age, yr | 48.73 ± 10.90 | 49.56 ± 12.01 | 53.83 ± 9.76 | .004 |
| HCVcAg, log10 fM | 4.53 ± 0.92 | 5.74 ± 0.50 | 6.43 ± 0.99 | .001 |
| HCVcAg, IU/mL | 5.73 ± 1.04 | 5.87 ± 0.09 | 7.46 ± 0.96 | .001 |
| ALT, UL | 112.02 ± 45.24 | 79.01 ± 44.32 | 68.39 ± 39.50 | .001 |
| AST, UL | 93.18 ± 43.05 | 65.37 ± 35.06 | 33.73 ± 6.74 | .001 |

ALT = alanine aminotransferase, AST = aspartate aminotransferase, HCVcAg = hepatitis C virus core antigen, N-SVR = nonsustained virologic response, SVR = sustained virologic response.
HCVcAg was an independent factor correlated with RVR, and HCV RNA, HCVcAg, and age were associated with EVR and SVR. HCVcAg more sensitively predicted RVR than HCV RNA and had a predictive capability similar to that of HCV RNA for EVR and SVR (Tables 2–4).

3.3. Kinetics of HCVcAg and HCV RNA

The dynamic changes in serum HCVcAg and HCV RNA were used to investigate their predictive values at different time points. The kinetics of serum HCVcAg and HCV RNA showed similar values in the SVR and N-SVR groups during the 72 weeks after treatment initiation but varied in patients after relapse (Fig. 1 and Table 5). Among the 3 groups, the decline in serum HCVcAg and HCV RNA in the SVR group was the most rapid, whereas that in the N-SVR group was the slowest. At 48 weeks, the value of HCV RNA decreased to 0 in the relapse group, whereas the value of HCVcAg was still above 0. Thus, HCVcAg might more sensitively predict relapse after antiviral therapy than HCV RNA.

3.4. ROC curves of HCVcAg and HCV RNA levels for prediction of SVR

The predictive values of HCVcAg and HCV RNA within the first 12 weeks of SVR were assessed by ROC curves (Fig. 2). According to the curves, some important parameters such as PPV, sensitivity, specificity, and NPV were 96.5%, 79.5%, 91.2%, and 91.2%, respectively; PPVs of HCVcAg and HCV RNA (91.2% and 97.1%, respectively) were similar across time points.

4. Discussion

To date, many methods including detection of specific antibody for HCV, HCV RNA, or HCVcAg and HCV genotyping have been used in the diagnosis, detection, and management of HCV infection.[19,20] Quantitative detection of HCVcAg and HCV RNA levels represents the 2 mainstay methods used for the management of patients with HCV infection.[21,22] However, owing to the high cost, time consumption, and requirement of dedicated laboratory area, large-scale detection of HCV RNA in many laboratories of developing countries is restricted.[22] Thus, HCVcAg quantification has been increasingly considered as a surrogate marker of CHC. Considering the differences in HCV pathogenesis, morbidity, and genotypes between Asian populations and European/American populations, HCVcAg assays could represent a more cost-effective method compared with HCV RNA quantification. However, HCVcAg testing has not been considered a gold standard for diagnosing and treating CHC.

### Table 2

| Variables | Coefficient | $\chi^2$ | OR (95% CI) | P |
|-----------|-------------|---------|-------------|---|
| HCV RNA, log_{10} copies/mL | −0.138 | 0.087 | 0.871 (0.326–2.324) | .782 |
| HCVcAg, log_{10} fM | 3.666 | 41.638 | 39.102 (7.085–215.768) | .001 |
| ALT, U/L | −0.063 | 0.764 | 0.959 (0.802–1.101) | .439 |
| AST, U/L | 0.047 | 0.374 | 1.048 (0.891–1.232) | .572 |
| Age, yr | −0.085 | 6.355 | 0.918 (0.743–1.482) | .118 |

CHC = chronic hepatitis C, CI = confidence interval, HCV = hepatitis C virus, OR = odds ratio, RVR = rapid virologic response, RNA = ribonucleic acid.

### Table 3

| Variables | Coefficient | $\chi^2$ | OR (95% CI) | P |
|-----------|-------------|---------|-------------|---|
| HCV RNA, log_{10} copies/mL | −0.460 | 1.913 | 0.632 (0.309–1.335) | .014 |
| HCVcAg, log_{10} fM | 3.206 | 43.489 | 24.682 (6.116–99.612) | .001 |
| ALT, U/L | −0.019 | 0.288 | 0.959 (0.914–1.003) | .861 |
| AST, U/L | 0.014 | 0.130 | 1.014 (0.940–1.094) | .320 |
| Age, yr | −0.042 | 8.060 | 0.959 (0.835–0.914) | .046 |

CHC = chronic hepatitis C, CI = confidence interval, HCV = hepatitis C virus, OR = odds ratio, RVR = rapid virologic response, RNA = ribonucleic acid.
Figure 1. Dynamic changes in serum HCVcAg (A) and HCV RNA (B) levels during antiviral treatment in different groups of patients. HCV = hepatitis C virus, HCVcAg = HCV core antigen, RNA = ribonucleic acid.

Table 5

|     | HCVcAg, log_{10} fM | HCV RNA, log_{10} copies/mL |
|-----|----------------------|-----------------------------|
|     | SVR | N-SVR | Relapse | SVR | N-SVR | Relapse |
| 0   | 4.53 | 6.43  | 5.74    | 5.65 | 7.53  | 6.85    |
| 4   | 1.75 | 5.38  | 4.71    | 3.36 | 6.26  | 5.91    |
| 12  | 0.39 | 4.61  | 3.13    | 0.49 | 5.98  | 4.23    |
| 16  | 0.15 | 1.92  | 1.25    | 0.17 | 3.1   | 2.24    |
| 20  | 0.09 | 1.88  | 1.39    | 0.03 | 2.96  | 0.81    |
| 24  | 0.02 | 1.84  | 0.25    | 0   | 2.92  | 0.26    |
| 48  | 0   | 1.65  | 0.3     | 0   | 2.63  | 0       |
| 72  | 0   | 1.78  | 4.82    | 0   | 2.89  | 6.32    |

HCV = hepatitis C virus, HCVcAg = HCV core antigen, N-SVR = nonsustained virological response, RNA = ribonucleic acid, SVR = sustained virological response.
HCV infection in China. Its clinical utility remains to be proven in large clinical trials.

In the present study, the correlation between HCV RNA and HCVcAg levels was analyzed using bivariate association analysis. Our study found a significant positive correlation between HCVcAg level and HCV RNA load but a low correlation between HCVcAg levels and ALT and AST levels, consistent with previous studies. For example, in comparison of different HCV RNA kits and the HCVcAg test, Medici et al revealed a correlation coefficient ranging from 0.713 to 0.870.

Recently, many studies have focused on the relevance of HCVcAg kinetics in the early prediction of SVR. However, only a few studies have investigated the difference between the HCVcAg test and HCV RNA test in predicting SVR, EVR, RVR, and relapse in patients treated with PEG-IFN and ribavirin for HCV genotype 1b infection. Our study used multivariate logistic regression analysis to reveal the association between influencing factors and the different outcomes of HCV genotype 1b infection treatment (EVR, RVR, and SVR).

An important finding of the present study was that HCVcAg and HCV RNA predicted EVR and SVR similarly, whereas for RVR, HCVcAg was a better predictor than HCV RNA, as HCVcAg was the only independent factor associated with RVR. Moreover, the dynamic changes in serum HCV RNA and HCVcAg in the 3 groups—SVR, N-SVR, and relapse—were tested. We found that during the 72 weeks after treatment initiation, kinetics of serum HCVcAg and HCV RNA showed similar values in the SVR, relapse, and N-SVR groups but varied in patients after relapse. This was consistent with previous findings that serum HCV RNA is undetectable in approximately

![Figure 2. ROC curves of HCVcAg and HCV RNA levels at weeks 4 and 12 to predict SVR. AUROC curve was calculated to compare the values of HCVcAg and HCV RNA at weeks 4 and 12 to predict SVR and identify the optimal cutoff values. The random classifier line indicates a 50% post-test probability, and the cutoff point represents the best compromise between sensitivity and specificity for the 2 assays. AUROC = area under the univariate receiver operating characteristic, SVR = sustained virological response.](image)

| Table 6 | Area under the ROC curve, sensitivity, specificity, and predictive values of the SVR based on total HCVcAg and HCV RNA levels at 4 and 12 weeks after treatment initiation. |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| | dHCVcAg4 | dHCVRNA4 | HCVcAg4 | HCVRNA4 | dHCVcAg12 | dHCVRNA12 | HCVcAg12 | HCVRNA12 |
| ROC (95% CI) | 0.705 (0.624–0.790) | 0.807 (0.724–0.970) | 0.812 (0.724–0.870) | 0.804 (0.688–0.870) | 0.912 (0.848–0.978) | 0.912 (0.861–0.963) | 0.923 (0.861–0.963) |
| Cutoff | 2.02 | 1.92 | 3.76 | 4.56 | 2.93 | 3.68 | 2.33 | 3.5 |
| Sensitivity | 0.625 | 0.529 | 0.802 | 0.878 | 0.854 | 0.954 | 0.954 | 0.965 |
| Specificity | 0.923 | 0.619 | 0.897 | 0.667 | 0.641 | 0.935 | 0.935 | 0.988 |
| PPV | 0.947 | 0.515 | 0.975 | 0.662 | 0.594 | 0.795 | 0.912 | 0.971 |
| NPV | 0.529 | 0.881 | 0.673 | 0.918 | 0.862 | 0.926 | 0.912 | 0.922 |

All data are presented as log10 values, and dHCVcAg and dHCVRNA were defined as a log10 reduction of serum HCVcAg and HCV RNA levels between other time points and baseline, respectively. AUROC = area under the univariate receiver operating characteristic curve, CI = confidence interval, HCVcAg = hepatitis C virus core antigen, NPV = negative predictive value, PPV = positive predictive value, RNA = ribonucleic acid.
50% of patients after IFN-based treatment for chronic HCV infection, thereby resulting in high rates of relapse.238

Among the 3 groups, the decline in serum HCVcAg and HCV RNA in the SVR group was the most rapid, whereas that in the NSVR group was the slowest. This result indicated that anti-HCV treatment outcomes can be predicted by HCVcAg determination. Interestingly, in the relapse group, the value of HCV RNA decreased to 0, whereas the value of HCVcAg remained relatively high at 48 weeks, suggesting that HCVcAg might be a more sensitive predictor of relapse after antiviral therapy compared with HCV RNA. We also assessed the best SVR predictive cutoffs of HCVcAg, dHCVcAg, HCV RNA, and dHCV RNA by calculating the AUROC curve at weeks 4 and 12. The results showed that at the same time points, the AUROC curve of HCVcAg or dHCVcAg was smaller than that of HCV RNA or dHCV RNA. The highest AUROC curve of 0.912 was obtained for HCVcAg levels, with a cutoff value of 2.23 at 12 weeks. The cutoff value yields of PPV and NPV were 91.2% and 91.2%, respectively. At the same time, compared with those of HCV RNA, the PPV and NPV of HCVcAg showed a smaller decline (91.2% and 97.1%). In addition, HCVcAg showed higher sensitivity than HCV RNA, indicating that HCVcAg is a more sensitive predictor of SVR in the treatment of HCV infection.

Our study had some limitations. First, the retrospective design may have introduced selection bias. Second, no randomization was performed in our study, and thus uncontrolled factors may have influenced the results. Third, the follow-up time was relatively short.

In conclusion, there was a strong correlation between HCV RNA and HCVcAg concentrations in individuals with HCV genotype 1b infection. In patients with CHC treated with PEG-IFN and ribavirin, serum HCVcAg had the same predictive efficacy for SVR and EVR as HCV RNA. Although HCVcAg and dHCVcAg had lower AUROC curve than HCV RNA and dHCV RNA, the sensitivity of the HCVcAg test was higher than that of HCV RNA, which implies that HCVcAg may have the same efficacy as HCV RNA in predicting SVR. We found that serum levels of HCVcAg were associated with RVR and relapse and might predict these events after antiviral therapy with higher sensitivity than HCV RNA. Thus, HCVcAg testing may represent an alternative approach to conventional HCV RNA quantification, with the advantages of speed, reproducibility, and reliability in settings with limited resources. Furthermore, HCVcAg could be a better independent factor for predicting RVR and relapse. In addition, combined analysis of HCVcAg and HCV RNA may be applied in clinical monitoring of CHC.

Author contributions

Conceptualization: Zhijuan Fan, Junfeng Liu, Shuyue Liu.
Data curation: Fengmei Wang.
Formal analysis: Zhijuan Fan, Junfeng Liu.
Funding acquisition: Shuyue Liu.
Investigation: Fengmei Wang, Jingmin Liu, Xian Ding.
Project administration: Shuyue Liu.
Resources: Jingmin Liu.
Software: Xian Ding.
Supervision: Zhijuan Fan, Junfeng Liu.
Validation: Fengmei Wang.
Visualization: Xian Ding.
Writing – original draft: Zhijuan Fan, Junfeng Liu.
Writing – review and editing: Shuyue Liu.

References

[1] World Health Organization. Hepatitis C Fact Sheet No. 164, 2014.
[2] Freeman RB Jr, Steffick DE, Guidinger MK, et al. Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant 2008;8:958-76.
[3] Omata M, Kanda T, Yu ML, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012;6:409-35.
[4] Lawitz E, Sulkowski MS, Ghalib R, et al. Simprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756-65.
[5] Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotypes 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016;16:683-97.
[6] Antaki N, Craxi A, Kamal S, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2010;30:342-55.
[7] Chakravarti A, Chauhan MS, Dogra G, et al. Hepatitis C virus core antigen assay: can we think beyond convention in resource limited settings? Braz J Infect Dis 2013;17:369-74.
[8] Kadkhodah K, Smart G. HCV antigen testing for the diagnosis of hepatitis C infection: a cost-efficient algorithm. Clin Lab 2014;60:677-80.
[9] Gupta E, Bajpai M, Choudhary A. Hepatitis C virus: screening, diagnosis, and interpretation of laboratory assays. Asian J Transfus Sci 2014;8:19-25.
[10] Miedouge M, Saune K, Kumar N, et al. Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J Clin Virol 2010;48:18-21.
[11] Tillmann HL. Hepatitis C virus core antigen testing: role in diagnosis, disease monitoring and treatment. World J Gastroenterol 2014;20:6701-6.
[12] Daniel HD, Vivekanandan P, Raghuraman S, et al. Significance of the hepatitis C virus (HCV) core antigen as an alternative plasma marker of active HCV infection. Indian J Med Microbiol 2007;25:37-42.
[13] Park Y, Lee JH, Kim BS, et al. New automated hepatitis C virus (HCV) core antigen assay as an alternative to real-time PCR for HCV RNA quantification. J Clin Microbiol 2010;48:2253-6.
[14] Hosseini-Moghaddam SM, Iran-Pour E, Rotstein C, et al. Hepatitis C virus core Ag and its clinical applicability: potential advantages and disadvantages for diagnosis and follow-up? Rev Med Virol 2012;22:156-65.
[15] Descaps V, Op de Beeck A, Plassart C, et al. Strong correlation between liver and serum levels of hepatitis C virus core antigen and RNA in chronically infected patients. J Clin Microbiol 2012;50:465-8.
[16] Garbuglia AR, Lionetti R, Lapa D, et al. The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavirin therapy in patients with HCV 1 genotype infection. J Clin Virol 2015;69:68-73.
[17] Feng B, Yang RF, Xie Q, et al. Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection. BMC Gastroenterol 2014;14:47.
[18] Craxi A, Pawlotsky JM. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of Hepatitis C Virus Infection. J Hepatol 2011;55:245-64.
[19] Yousaf MZ, Idrees M, Saleem Z, et al. Expression of core antigen of HCV genotype 3a and its evaluation as screening agent for HCV infection in Pakistan. Virol J 2011;8:364-70.
[20] Idrees M, Ur Rehman I, Manzoor S, et al. Evaluation of three different hepatitis C virus typing methods for detection of mixed-genotype infections. J Dig Dis 2011;12:199-203.
[21] Buruk K, Bayramoglu G, Kaklikkaya N, et al. Correlation between architect hepatitis C virus (HCV) core antigen and HCV ribonucleic acid levels in anti-HCV reactive patients in Turkey. Afr J Microbiol Res 2013;7:4907-11.
[22] Laprèche S, Rouger P, Smolovic W, et al. Alternatives to nucleic acid testing in the blood transfusion service. Lancet 2002;360:1519-20.
[23] EASL Clinical Practice Guidelines: Management of Hepatitis C Virus Infection. J Hepatol 2014;60:392-420.
[24] Medici MC, Furlini G, Rodella A, et al. Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. J Clin Virol 2011;51:264-9.
[25] Ottiger C, Gygli N, Huber AR. Detection limit of architect hepatitis C core antigen assay in correlation with HCV RNA, and renewed confirmation algorithm for reactive anti-HCV samples. J Clin Virol 2013;58:535–40.

[26] Kuo YH, Chang KC, Wang JH, et al. Is hepatitis C virus core antigen an adequate marker for community screening? J Clin Microbiol 2012;50:1989–93.

[27] Soliman HA, Hozayen WG, Mahmoud AM, et al. Significance of the hepatitis C virus core antigen testing as an alternate marker for hepatitis diagnosis in Egyptian patients. Eur Rev Med Pharmacol Sci 2014;19:2240–5.

[28] Pham TN, MacParland SA, Mulrooney PM, et al. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2004;78:5867–74.